Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001304654 | SCV001493947 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-01-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 1171 of the ATM protein (p.Gln1171Glu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 1007468). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001664815 | SCV001874876 | uncertain significance | not provided | 2021-08-11 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (Lek 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 19781682) |
Fulgent Genetics, |
RCV005040154 | SCV005681265 | uncertain significance | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2024-02-07 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001304654 | SCV002080485 | uncertain significance | Ataxia-telangiectasia syndrome | 2021-06-24 | no assertion criteria provided | clinical testing |